Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Westlake Corporation (WLK): Initiation of Coverage -Turnarounds, Cost Discipline & HIP Resilience Drive Margin Rebuild — What’s the Impact, Valuation Outlook & its 5 Key Catalysts?
Westlake’s Q1 2025 print showcased its portfolio’s defensiveness amid a tough macro tape, with consolidated EBITDA of $288M dragged by a 71% YoY contraction in Performance & Essential Materials (PEM), where $180M in combined feedstock inflation and outage-related headwinds compressed margins to just 4%. While PEM volume and ASP declines reinforced cyclical fragility, completed turnarounds at Petro 1 and Geismar set the stage for margin normalization into Q2. Housing & Infrastructure Products (HIP) proved more stable, sustaining 20% EBITDA margin despite prebuy unwind and construction delays, with sequential volume growth and reaffirmed full-year guide (albeit at the lower end) reflecting underlying resilience. Management raised FY25 cost savings target to $175M, trimmed capex 10% to $900M, and accelerated European Epoxy restructuring to address persistent underperformance, moves we view as necessary for margin rebuild. The balance sheet remains strong ($2.5B in cash vs. $4.6B in debt), affording strategic flexibility for opportunistic buybacks and counter-cyclical capex. While PEM recovery visibility remains clouded by ethane/natgas volatility, tariffs, and global chlorovinyl price pressure, HIP’s cash-generation and PEM’s operational resets offer asymmetric upside. Can Westlake’s completed turnarounds, stepped-up cost discipline, and HIP stability anchor a convincing earnings recovery as commodity spreads start to mean-revert in 2H25?
